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Abstract
GLP-1 receptors are ideal targets for preoperative imaging of benign insulinoma and for
quantifying the beta cell mass. The existing clinical tracers targeting GLP-1R are all agonists
with low specific activity and very high kidney uptake. In order to solve those issues we evalu-
ated GLP-1R agonist Ex-4 and antagonist Ex(9–39) radioiodinated at Tyr40 side by side with
[Nle14,Lys40(Ahx-DOTA-68Ga)NH2]Ex-4 (68Ga-Ex-4) used in the clinic. The Kd, Bmax, inter-
nalization and binding kinetics of [Nle14,125I-Tyr40-NH2]Ex-4 and [Nle14,125I-Tyr40-NH2]Ex
(9–39) were studied in vitro using Ins-1E cells. Biodistribution and imaging studies were per-
formed in nude mice bearing Ins-1E xenografts. In vitro evaluation demonstrated high affinity
binding of the [Nle14,125I-Tyr40-NH2]Ex-4 agonist to the Ins-1E cells with fast internalization
kinetics reaching a plateau after 30 min. The antagonist [Nle14,125I-Tyr40-NH2]Ex(9–39) did
not internalize and had a 4–fold higher Kd value compared to the agonist. In contrast to
[Nle14,125I-Tyr40-NH2]Ex(9–39), which showed low and transient tumor uptake, [Nle14,125I-
Tyr40-NH2]Ex-4 demonstrated excellent in vivo binding properties with tumor uptake identical
to that of 68Ga-Ex-4, but substantially lower kidney uptake resulting in a tumor-to-kidney ratio
of 9.7 at 1 h compared to 0.3 with 68Ga-Ex-4. Accumulation of activity in thyroid and stomach
for both peptides, which was effectively blocked by irenat, confirms that in vivo deiodination is
the mechanism behind the low kidney retention of iodinated peptides. The 124I congener of
[Nle14,125I-Tyr40-NH2]Ex-4 demonstrated a similar favourable biodistribution profile in the
PET imaging studies in contrast to the typical biodistribution pattern of [Nle14,Lys40(Ahx-
DOTA-68Ga)NH2]Ex-4. Our results demonstrate that iodinated Ex-4 is a very promising tracer
for imaging of benign insulinomas. It solves the problem of high kidney uptake of the radiome-
tal-labelled tracers by improving the tumor-to-kidney ratio measured for [Nle14,Lys40(Ahx-
DOTA-68Ga)NH2]Ex-4 by 32 fold.
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Introduction
Glucagon like peptide-1 receptors (GLP-1R) are ideal targets for the imaging of benign insuli-
noma due to their high density on the surface of more than 90% of these tumors [1]. Physio-
logical expression of GLP-1 receptors on the pancreatic beta cells is also being exploited
preclinically and potentially clinically for imaging of the pancreatic beta cell mass to quantify
the loss of islets in type 1 diabetes [2,3]. Since islet transplantation may be a promising treat-
ment option for patients with diabetes, the GLP-1 targeted imaging is being explored for visu-
alization of transplanted islets and monitoring their survival [4,5].
In case of benign insulinoma, preoperative localization plays a crucial role in the successful
outcome of the surgery and in sparing the healthy pancreatic tissue. However, due to the small
size of insulinoma lesions (often less than 2 cm) the precise localization is very challenging
using conventional imaging techniques having a sensitivity of only 47% [6]. This prompted an
intensive research into developing more sensitive and non-invasive imaging modalities to
localize benign insulinoma in the pancreas. A variety of GLP-1R targeting peptide probes
labelled with 111In [7,8], 99mTc [8], 123I [9] for SPECT and with 68Ga [3,8,10–13], 64Cu [3,14],
18F [5,15,16], and 89Zr [13] for PET imaging showed promising results in preclinical studies.
Some of the tracers have been successfully translated into the clinic [17–22] and showed high-
est sensitivity among the available techniques in detecting ‘‘hidden” insulinomas in patients.
Despite the great clinical potential, several aspects of the existing GLP-1R specific tracers
would greatly benefit from further improvements. Firstly, the high and persistent kidney uptake
of radiometal-labelled tracers not only leads to an unnecessary high radiation dose to the kidney
but also can complicate the preoperative and intraoperative insulinoma detection in the head
and tail of the pancreas [17,20,23]. Secondly, the specific activity of the existing tracers is rela-
tively low requiring higher peptide mass for adequate activity to achieve a good image quality.
The agonist peptide dose is however limited due to the risk of insulin-related side effects. GLP-1
receptor agonists belong to the potent incretin hormones; after binding to the receptor they inter-
nalize and activate GLP-1 receptor signalling leading to the glucose-dependent insulin secretion.
For this reason, antagonist probes would be much more attractive because they would not
activate the downstream signalling. Moreover, antagonist ligands for other G-protein coupled
receptors (GPCRs), including gastrin-releasing peptide receptor and somatostatin receptors
have been shown to target more binding sites and as a result to have higher tumor uptake than
agonists [24,25]. Exendin(9–39) isolated from Heloderma suspectum venom was identified as
GLP-1 receptor antagonist binding with high affinity [26]. There are only few reports on radio-
labeled Ex(9–39)-based tracers showing that Ex(9–39) derivatives radiolabeled with 68Ga [27]
or 18F [28] are not suitable for imaging due to the low tumor uptake.
Our recent data also demonstrate that in contrast to Ex-4-based tracers, which tolerated
various modifications at the C-terminal very well, the Ex(9–39) antagonist was very sensitive
to conjugation of the 68Ga-DOTA or 68Ga-NODAGA complexes at the positions Lys27 or
Lys40 [29]. The resulting probes had low affinity and were not suitable for GLP-1 R imaging
[29]. However, Ex(9–39) radioiodinated with 125I at Lys27 using the Bolton Hunter (BH)
method showed the same binding properties for the human GLP-1 receptor-expressing tissues
in vitro as endogenous GLP-1 [30]. We demonstrated that in vivo 125I-BH-Ex(9–39) accumu-
lated in the Ins-1E xenografts with an uptake similar to that of 68Ga-Ex-4, the GLP-1R tracer
currently used in the clinic [22]. Most importantly, however radioiodination resulted in a sig-
nificant reduction of the radioligand’s kidney uptake [29]. In comparison to 68Ga-Ex-4, the
tumor-to-kidney ratio of 125I-BH-Ex-(9–39) improved 20-fold.
However, the Bolton-Hunter method is not so trivial to translate into the clinic. In the cur-
rent study we selected the direct iodination approach, because it is a one-step process and the
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in vivo deiodination efficiency of 125I-Tyr is even higher than that for 125I-BH [31]. As a conse-
quence the kidney uptake can be expected to be even lower for the directly iodinated peptides.
Since radioiodination of Ex(9–39) with 125I-BH at position Lys27 was tolerated better than con-
jugation of 68Ga-DOTA or 68Ga-NODAGA in the same position, we hypothesized that radio-
iodination at the C-terminal Tyr40 may also potentially lead to a GLP-1R antagonist tracer
with high affinity and favourable pharmacokinetics. In this study, the Ex-4 agonist and Ex(9–
39) antagonist radioiodinated at the Tyr40 residue were evaluated in vitro and in vivo and com-
pared side by side to the reference compound, [Nle14,Lys40(Ahx-DOTA-68Ga)NH2]Ex-4.
Materials and Methods
Reagents and instruments
All reagents and solvents were purchased from Sigma-Aldrich (Taufkirchen, Germany) and
Carl Roth GmbH & Co. KG (Karlsruhe, Germany). The details for the analytical and semi-pre-
parative HPLC set up are described in the S1 File.
Peptides and radioiodination
[Nle14,Tyr40-NH2]Ex-4 and [Nle
14,Tyr40-NH2]Ex-(9–39) precursor peptides were purchased
from Biotrend Chemikalien GmbH (Ko¨ln, Germany). [Nle14,125I-Tyr40-NH2]Ex-4 and
[Nle14,125I-Tyr40-NH2]Ex(9–39) were produced from precursor peptides by Celerion (Zu¨rich,
Switzerland) using the Chloramine-T method. [Nle14,127I-Tyr40-NH2]Ex-4 and [Nle
14,127I--
Tyr40-NH2]Ex(9–39), the corresponding non-radioactive reference peptides were custom-syn-
thesized by Peptide Specialty Laboratories GmbH (Heidelberg, Germany) and Biotrend
Chemikalien GmbH (Ko¨ln, Germany), respectively, using a Fmoc-protected 3-iodotyrosine as
a building block.
[Nle14,124I-Tyr40-NH2]Ex-4 was prepared from [Nle
14,Tyr40-NH2]Ex-4 using I-124 (Per-
kin-Elmer, Boston, USA) carrier-free (theoretical specific activity of I-124 is 1147 TBq/mmol),
employing the Chloramine-T method following a published protocol [32] with minor modifi-
cations (for the details please see S2 File).
In vitro binding assays
Ins-1E cells (a gift from Dr. Gu¨nter Pa¨th) were maintained in RPMI medium, containing 10%
FBS, 1mM sodium pyruvate, 50 μM ß-mercaptoethanol, 10 mM HEPES (pH 7.2), Penicillin G
(100 IA/ml) and Streptomycin (10 mg/ml). One day prior to the experiments, cells (1.8 × 106)
were plated in triplicates in the 6-well plates. For the saturation binding experiment, cells were
incubated with 3 kBq of [Nle14,125I-Tyr40-NH2]Ex-4 and increasing amounts of [Nle
14, 127I-
Tyr40-NH2]Ex-4 peptide (1–100 nM) in the growth medium, containing 1%FBS for 2 hours at
+4˚C. To determine the non-specific binding, three additional wells were blocked with 1 μM
of [Nle14,127I-Tyr40-NH2]Ex-4. After washing with cold PBS cell bound activity was collected
with 1M NaOH (3x1 ml). For internalization experiments, Ins-1E cells were incubated with 5
kBq of [Nle14,125I-Tyr40-NH2]Ex-4, containing 1 nM of [Nle
14,127I-Tyr40-NH2]Ex-4 at 37˚C.
At specific time points the internalization was stopped by washing the cells with ice-cold PBS
and the membrane bound and internalized activity were collected as described previously [33].
125I-radioactivity in samples was measured using a gamma counter (Cobra 5003; Packard
Instruments). The percentage of specifically bound activity per 1x106 cells was assessed by
comparison with standards and non-specific controls.
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Xenograft model and biodistribution studies
All animal experiments were conducted in accordance with the German animal protection law
(TierSchG). The protocol was approved by the Animal Welfare Ethics committees of the Uni-
versity of Freiburg (Regierungspra¨sidium Freiburg Az G-12/21). Female Balb/c Nude mice
(18–20 g, 6–8 weeks old) were obtained from Janvier Labs (Saint-Berthevin Cedex, France)
and were housed and handled in accordance with the good animal practice as defined by
FELASA and the national animal welfare body GVSOLAS. Xenografts were established on the
right shoulder by s.c. injection of 7 million of Ins-1E cells in 1:1 v/v mixture of PBS and matri-
gel (final volume 100 μl). Mice were fed 60% Glucose Diet (PROVIMI KLIBA SA, Kaiseraugst,
Switzerland).
Ins-1E tumor-bearing mice were administered with 40 kBq of [Nle14,125I-Tyr40-NH2]Ex-4
or [Nle14,125I-Tyr40-NH2]Ex(9–39) in 100 μL sterile saline via intravenous (i.v.) tail-vein injec-
tion. For mass dependence 10 or 100 pmol of [Nle14, 127I-Tyr40-NH2]Ex-4 or 10 pmol of
[Nle14,127I-Tyr40-NH2]Ex(9–39) were coinjected together with the radioiodinated peptide. For
the blocking experiment, 80 nmol of Ex(9–39) was injected 5 minutes before the administra-
tion of iodinated peptide. The sodium iodide symporters were blocked by Irenat (Bayer) (120
mg/kg, i.v.). Animals (n = 3–4, per group) were euthanized by asphyxiation with excess isoflur-
ane at 1, 4 and 24 h post-radiotracer administration, and tissues were removed, rinsed in
water, dried in air, weighed and counted on a calibrated and normalized gamma-counter.
Small-animal PET/CT imaging
Mice were injected iv with [Nle14,124I-Tyr40-NH2]Ex-4 (2.5–3.0 MBq in 100 μL sterile saline).
At 1, 2 and 4 hour post injection 20–40 minute static scans were acquired using microPET
Focus 120 scanner (Concorde Microsystems), followed by 2 minute CT scans on micro-CT-
Tomoscope Synergy (CT Imaging GmbH). PET sinograms were reconstructed using a 2-
dimensional ordered-subset expectation maximization (2D-OSEM) algorithm. Image counts
per pixel per second were calibrated to activity concentrations (Bq/mL) by measuring a 3.5 cm
cylinder phantom filled with a known concentration of radioactivity. The PET and CT images
were co-registered using the Rover software (ABX, Radeberg, Germany). PET images were
analyzed using Rover software (ABX, Radeberg, Germany). The regions of interest were
drawn based on the CT to include the entire tumor or the kidney and the mean %IA/g was
calculated. For the time activity curves the PET images recorded at 1, 2 and 4 h p.i. were
merged together and the mean %IA/g were calculated from the VOI placed in the same
position in the tumor.
Statistical analysis
A statistical analysis was performed using GraphPad Prism 5.01 (GraphPad Software, Inc) and
Microsoft Excel. Data were analyzed by using the unpaired, two-tailed Student’s t-test.
Results
Peptides
The chemical purity of the precursor peptides for radioiodination, [Nle14,Tyr40-NH2]Ex-4 and
[Nle14,Tyr40-NH2]Ex(9–39), and the non-radioactive reference peptides,[Nle
14,127I-Tyr40-
NH2]Ex-4 and [Nle
14,127I-Tyr40-NH2]Ex(9–39) was determined by analytical HPLC to be
>95%. Compounds were characterized by either ESI-MS or MALDI-MS and the obtained
masses matched the exact calculated masses for all compounds (S1 Table).
PET Imaging of Insulinomas
PLOS ONE | DOI:10.1371/journal.pone.0170435 January 19, 2017 4 / 16
Radiochemical purity and in vitro characterization of [Nle14,125I-Tyr40-
NH2]Ex-4 and [Nle14,125I-Tyr40-NH2]Ex(9–39)
[Nle14,125I-Tyr40-NH2]Ex-4 and [Nle
14,125I-Tyr40-NH2]Ex(9–39) were delivered carrier-free,
with a specific activity of 81.4 TBq/mmol and a radiochemical purity of> 95% (S1 and S2
Figs). The identity of the radioiodinated peptides was confirmed by coinjection with the corre-
sponding non-radioactive reference peptides, containing 127I (S1 and S2 Figs).
The in vitro binding properties of the [Nle14,125I-Tyr40-NH2]Ex-4 agonist and [Nle14,125I-
Tyr40-NH2]Ex(9–39) antagonist were studied using Ins-1E cells, expressing the rat GLP-1
receptor. The results of the saturation binding experiments demonstrate that [Nle14,125I-Tyr40-
NH2]Ex-4 bound to Ins-1E cells with a Kd of 4.1±1.1 nM and a Bmax of 0.045±0.002 nM (Fig
1A). [Nle14,125I-Tyr40-NH2]Ex(9–39), in contrast, had a Kd value of 18.1±6.9 nM and a Bmax
value of 0.071±0.007 nM (Fig 1B). Fig 2 shows cell binding and internalization kinetics of the
[Nle14,125I-Tyr40-NH2]Ex-4 and [Nle
14,125I-Tyr40-NH2]Ex(9–39) in Ins-1E cells. The amount
of internalized [Nle14,125I-Tyr40-NH2]Ex-4 after 0.5 h at 37˚C was 3.12±0.11% reaching 3.75
±0.06% after 4 h (Fig 2A), while the amount of specifically bound [Nle14,125I-Tyr40-NH2]Ex-4
reached 0.53±0.01% after 0.5 h and remained the same until 4 hours (Fig 2B). The antagonist
[Nle14,125I-Tyr40-NH2]Ex(9–39) showed very different kinetics with a significantly higher per-
centage of specifically bound peptide (1.82±0.09%) and a lower amount of internalized peptide
(0.52±0.05%) at 0.5 h. After 4 h the amount of bound peptide remained the same (Fig 2B) and
the amount of internalized peptide increased slightly to 0.68±0.03% (Fig 2A).
Biodistribution of [Nle14,125I-Tyr40-NH2]Ex-4
At 1 hour post injection (p.i.) of [Nle14,125I-Tyr40-NH2]Ex-4 the highest uptake was found in
the Ins-1E tumor (72.8±12.2%IA/g) followed by the lung (30.5±3.6%IA/g) and the pancreas
(25.3±4.2%IA/g) (Table 1). Blocking with an excess of GLP-1 receptor antagonist reduced the
uptake in the Ins-1E tumor, lung and pancreas by 92%, 93% and 93%, respectively. Addition-
ally, 13.4±1.2%IA/g accumulated in the stomach and the blocking reduced the stomach uptake
by 30%. Importantly, the kidney uptake was very low, only 7.5±0.7%IA/g, resulting in a very
favourable tumor-to-kidney ratio of 9.7 at 1 hour p.i. (Table 1). The tumor-to-blood and
tumor-to-muscle ratios at 1 hour p.i. were 25.1 and 182, respectively.
After 4 hours p.i. there was a washout of activity from the target organs at a comparable rate
with 22.4±2.9%IA/g, 10.4±2.5%IA/g, and 8.8±1.8%IA/g remaining in the tumor, pancreas and
Fig 1. In vitro saturation binding data. The graphs show the percentage of specifically bound [Nle14,125I-Tyr40-NH2]Ex-4
(A) or [Nle14,125I-Tyr40-NH2]Ex(9–39) (B) per 1×106 cells after incubation of Ins-1E cells with increasing amounts of the
peptide. Values are mean±standard error of triplicate measurements.
doi:10.1371/journal.pone.0170435.g001
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lung, respectively. Tumor-to-normal organ ratios at 4 hours p.i. were lower than at 1 hour p.i.
(Table 1). At 24 hours p.i. most of the radioactivity was cleared from the body with 3.7±2.5%
IA/g still remaining in the tumor (Table 1).
At one hour p.i. of [Nle14,125I-Tyr40-NH2]Ex-4 1.4±0.1%IA/organ was accumulated in the
thyroid, confirming the dehalogenation of the tracer in vivo. However, blocking the sodium
iodide symporter with irenat reduced the thyroid uptake by 94% (Table 2).
Fig 2. Internalization (A) and binding (B) curves for [Nle14,125I-Tyr40-NH2]Ex-4 agonist and
[Nle14,125I-Tyr40-NH2]Ex(9–39) antagonist in Ins-1E cells. The plots show the percentage of specifically
internalized and specifically bound peptide versus time. Values are mean±standard deviation of triplicate
measurements.
doi:10.1371/journal.pone.0170435.g002
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Among the three studied peptide doses of [Nle14,125I-Tyr40-NH2]Ex-4 (0.5 pmol, 10 pmol
and 100 pmol) the lowest peptide mass of 0.5 pmol corresponding to the highest specific activ-
ity showed the most favourable biodistribution profile with highest tumor uptake and highest
tumor-to-normal organ ratios (Table 2).
Biodistribution of [Nle14,125I-Tyr40-NH2]Ex(9–39)
Corresponding to the lower affinity of the antagonist, also the tumor uptake of [Nle14,125I--
Tyr40-NH2]Ex(9–39) was lower, 12.7±4.1%IA/g at 1 h p.i. and it decreased after 4 h to 1.9±0.5%
IA/g, similar to the activity in the blood pool (Table 3). The uptake in other receptor-expressing
organs was also lower (Table 3). Blocking with an excess of cold antagonist reduced the uptake
in the tumor, pancreas and lung by 80%, 93% and 88% respectively (Table 3). The uptake in
the kidney at 1 h p.i. was also very low (7.6±1.2%IA/g) and identical to the agonist kidney up-
take. However, due to the lower tumor uptake, the tumor-to-kidney ratio dropped to 1.7. The
tumor-to-blood and tumor-to muscle ratios of [Nle14,125I-Tyr40-NH2]Ex(9–39) were substan-
tially lower than the ratios for the agonist. The uptake in the thyroid was 1.3±0.2%IA/organ at 1
h p.i., indicating tracer deiodination in vivo. In terms of the peptide dose, the lowest dose of 0.5
pmol yielded the highest tumor uptake and best tumor-to-normal organ ratios (Table 3).
Biodistribution of the [Nle14,Lys40(Ahx-DOTA-68Ga)NH2]Ex-4 reference
tracer
For the direct comparison, we studied the biodistribution of the 68Ga-labelled Ex-4 tracer in
the same tumor model. At 1 h p.i. of 10 pmol of [Nle14,Lys40(Ahx-DOTA-68Ga)NH2]Ex-4, the
Table 1. Biodistribution of [Nle14,125I-Tyr40-NH2]Ex-4 in mice bearing Ins-1E xenografts.
Organ %IA/g #
1 h a 1 h–blocked 4 h 24 h
Blood 2.9±0.2 2.9±0.5 2.2±0.2* 0.1±0.0**
Heart 1.3±0.2 0.7±0.1* 0.8±0.1* 0.1±0.0**
Lung 30.5±3.6 2.2±0.0** 8.8±1.8** 0.1±0.0**
Liver 1.5±0.1 1.1±0.3 0.8±0.0 0.1±0.0**
Spleen 1.5±0.3 1.1±0.2 1.1±0.1** 0.1±0.0**
Pancreas 25.3±4.2 1.9±0.1** 10.4±2.5** 0.9±0.5**
Stomach 13.4±1.2 9.3±0.6* 8.3±2.1* 0.3±0.0**
Intestine 3.9±0.5 1.3±0.2** 1.8±0.4** 0.1±0.0**
Kidney 7.5±0.7 5.7±0.1* 3.2±0.3** 0.2±0.0**
Adrenal 1.4±0.3 0.8±0.2 0.8±0.4 0.2±0.1**
Muscle 0.4±0.0 0.5±0.0 0.3±0.0* 0.1±0.0**
Bone 0.6±0.4 1.0±0.3 0.7±0.1 0.1±0.0
Ins-1E 72.8±12.2 5.9±0.6** 22.4±2.9** 3.7±2.5**
Tumor-to-blood 25.1 10.2 37
Tumor-to-muscle 182 74.7 37
Tumor-to-kidney 9.7 7.0 18.5
Tumor-to-pancreas 2.9 2.2 4.1
# Values are mean±standard deviation (n = 3–4).
a
-The peptide mass is 0.5 pmol, based on the specific activity of 125I.
*p<0.05.
**p<0.01, compared to 1h group.
doi:10.1371/journal.pone.0170435.t001
PET Imaging of Insulinomas
PLOS ONE | DOI:10.1371/journal.pone.0170435 January 19, 2017 7 / 16
kidney had the highest accumulation of activity (201.3±30.6%IA/g) followed by the Ins-1E
tumor (58.3±15.6% IA/g), the pancreas (25.5±5.2% IA/g), and the lung (14.3±1.2%IA/g). The
tumor-to-blood and tumor-to-muscle ratios were 48.5 and 215.9, respectively (Table 4). The
tumor-to-kidney ratio was very low, only 0.3.
Synthesis and in vitro characterization of [Nle14,124I-Tyr40-NH2]Ex-4
Given the high tumor uptake and excellent tumor-to-kidney ratios obtained with [Nle14,125I--
Tyr40-NH2]Ex-4, we proceeded to prepare the corresponding
124I-labeled analogue, which
would be suitable for PET-imaging studies. Radiosynthesis was performed using the chlora-
mine-T method. The semi-preparative HPLC chromatogram of the crude [Nle14,124I-Tyr40-
NH2]Ex-4 (S3 Fig) demonstrates that the peptide precursor [Nle
14,Tyr40-NH2]Ex-4 elutes
about 3 min earlier than the iodinated product [Nle14,124I-Tyr40-NH2]Ex-4, enabling isolation
of the pure radio-iodinated tracer with high specific activity (S3 Fig). The collected product
fractions from several syntheses were combined, trapped on a C8-SepPak, and eluted with eth-
anol to yield formulated [Nle14,124I-Tyr40-NH2]Ex-4 in 18.0±1.6% (n = 3) radiochemical yield
and>95% radiochemical purity (Fig 3A and 3B).
In vitro evaluation revealed that [Nle14,124I-Tyr40-NH2]Ex-4 bound to the cells with a Kd of
6.5±1.7 nM and a Bmax of 0.038±0.003 nM (Fig 4).
Table 2. Mass dependence of [Nle14,125I-Tyr40-NH2]Ex-4 biodistribution in nude mice bearing Ins-1E
xenografts 1 h p.i.
Organ %IA/g #
10 pmol %IA/g 100 pmol 10 pmol + irenat
Blood 3.9±0.2** 4.1±0.4** 4.1±0.4**
Heart 1.2±0.2 1.1±0.1 1.3±0.3
Lung 12.9±1.1** 5.5±0.8** 14.6±2.5**
Liver 1.4±0.1 1.5±0.1 1.6±0.2
Spleen 1.5±0.1 1.5±0.1 1.4±0.1
Pancreas 22.9±2.2 8.4±0.8** 19.9±5.9
Stomach 12.2±1.2 10.9±0.2* 5.3±0.9**
Intestine 2.6±0.7 1.7±0.1 2.1±0.2**
Kidney 7.9±1.1 7.5±0.8 8.5±1.9
Adrenal 1.2±0.5 0.9±0.2 1.2±0.1
Muscle 0.4±0.1 0.4±0.1 0.6±0.1
Bone 0.9±0.1 0.9±0.2 1.0±0.1
Ins-1E 56.3±8.1 20.3±3.5** 60.0±22.7
Thyroid a 1.4±0.1a 0.1±0.0a**
Tumor-to-blood 14.4 5.0 14.6
Tumor-to-muscle 140.8 50.8 100.0
Tumor-to-kidney 7.1 2.7 7.1
Tumor-to-pancreas 2.5 2.4 3.0
# Values are mean±standard deviation (n = 3–4).
*p<0.05.
**p<0.01, compared to the 1h / 0.5 pmol group of Table 1 (for the thyroid, comparison is against the 1h /
10pmol group of Table 2).
a Thyroid uptake is reported as %IA/organ. Reason for this is the complicated delineation of the thyroid,
which resulted in excision of variable amounts of adjacent tissue upon dissection and concomitantly
incorrect values when uptake is reported as %IA/g.
doi:10.1371/journal.pone.0170435.t002
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PET imaging of GLP-1 receptors in mice using [Nle14,124I-Tyr40-NH2]
Ex-4
The in vivo properties of [Nle14,124I-Tyr40-NH2]Ex-4 were evaluated using PET imaging. Max-
imum-Intensity-Projection (MIP) PET images (Fig 5A, 1st panel) demonstrate that at 1 hour
p.i. of [Nle14,124I-Tyr40-NH2]Ex-4, the highest specific uptake was detected in Ins-1E tumor
(10.8%IA/g based on image quantification). In the blocked mouse (Fig 5A, 2nd panel) the
tumor uptake was inhibited by 82% (1.9%IA/g left in the tumor). Apart from the bladder, high
accumulation of radioactivity was also found in the thyroid (19.7%IA/g) and the stomach
(28.3%IA/g) confirming the tracer radiodeiodination in vivo. The stomach uptake was partially
inhibited in the blocked mouse, suggesting some GLP-1 receptor mediated uptake in the stom-
ach, which was also described by others in the field. Blocking of the sodium iodide symporter
with irenat did not affect the tumor uptake (11.4%IA/g) but completely inhibited the thyroid
uptake and most of the stomach uptake (Fig 5A, 3rd panel).
The high amount of radioactivity in the bladder already after 1 hour p.i. suggests that the
tracer or its radiometabolites are cleared through the kidney. Finally, HPLC analysis of the
urine taken at 1 and 4 h p.i. of [Nle14,124I-Tyr40-NH2]Ex-4 revealed that there was only free
124I-iodide and no intact peptide present in the mouse urine (S4 Fig).
The tumor time-activity curve derived from quantification of the PET images recorded at 1,
2, and 4 hours p.i. of irenat and [(Nle14,124I-Tyr40)NH2]Ex-4 shows a decrease in the tumor
radioactivity from 11.4%IA/g at 1 h p.i. to 5.4%IA/g at 4h p.i. (Fig 6).
Table 3. Biodistribution of [Nle14,125I-Tyr40-NH2]Ex(9–39) in mice bearing Ins-1E xenografts.
Organ %IA/g #
1 ha 1 h–blocked 1 h– 10 pmol 4 h
Blood 4.2±0.5 3.2±0.2 4.4±0.1 2.0±0.4*
Heart 1.3±0.2 0.9±01 1.2±0.0 0.5±0.1*
Lung 13.6±1.0 1.7±0.4** 9.8±0.9* 3.3±1.2**
Liver 3.2±0.5 1.5±0.7* 2.9±0.3 0.9±0.2**
Spleen 1.5±0.2 1.1±0.1 1.7±0.1 0.8±0.1*
Pancreas 17.93±1.41 1.3±0.4** 17.8±2.4 3.6±1.2**
Stomach 11.9±1.6 12.0±0.7 11.2±3.6 5.3±1.9*
Intestine 2.4±0.4 2.2±0.5 3.8±1.9 1.1±0.0*
Kidney 7.6±1.2 4.2±0.2* 7.2±0.6 2.0±0.3**
Adrenal 1.3±0.4 0.6±0.5 1.3±0.1 0.5±0.1*
Muscle 0.7±0.2 0.6±0.0 1.2±0.7 0.6±0.4
Bone 1.2±0.1 1.4±0.6 1.3±0.2 0.8±0.3*
Ins-1E 12.7±4.1 2.6±0.8* 9.5±2.7 1.9±0.5*
Thyroidb n.d n.d. 1.3±0.2 n.d.
Tumor-to-Blood 3.1 2.2 1.0
Tumor-to-Muscle 17.8 7.7 3.3
Tumor-to-Kidney 1.7 1.3 1.0
Tumor-to-pancreas 0.7 0.5 0.5
# Values are mean±standard deviation (n = 3–4).
a the peptide mass is 0.5 pmol, based on the specific activity of 125I.
b
—thyroid uptake is reported as %IA/organ.
*p<0.05.
**p<0.001, compared to the 1 h group.
n.d.—not determined.
doi:10.1371/journal.pone.0170435.t003
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The MIP PET image of the reference GLP-1 receptor imaging agent [Nle14,Lys40(Ahx-
DOTA-68Ga)NH2]Ex-4 at 1 h p.i (Fig 5B) demonstrates a typical biodistribution profile for the
radiometal labelled Ex-4 analogue with a high tumor uptake but also very high uptake in the
kidney.
Discussion
GLP-1 receptor targeting peptides are important imaging tools for preoperative localization of
benign insulinoma. Currently available tracers show a high and persistent renal uptake and
low specific activity, resulting in side effects such as hypoglycaemia due to insulin secretion
Table 4. Biodistribution of 10 pmol of [Nle14,Tyr40(Ahx-DOTA-68Ga)NH2] in mice bearing Ins-1E xeno-
grafts at 1 h p.i.
Organ %IA/g #
Blood 1.2±0.3
Heart 0.7±0.1
Lung 14.3±1.2
Liver 2.1±0.3
Spleen 1.9±0.7
Pancreas 25.5±5.2
Stomach 5.8±1.8
Intestine 1.9±0.4
Kidney 201.3±30.6
Adrenal 2.2±0.9
Muscle 0.3±0.2
Bone 0.610.2
Ins-1E 58.3±15.6
Tumor-to-Blood 48.6
Tumor-to-Muscle 215.9
Tumor-to-Kidney 0.3
Tumor-to-Pancreas 2.3
# Values are mean±standard deviation (n = 3–4).
doi:10.1371/journal.pone.0170435.t004
Fig 3. Radio-HPLC showing the radiochemical purity of formulated [Nle14,124I-Tyr40-NH2]Ex-4 without
(A) and with co-injection of cold reference [Nle14,127I-Tyr40-NH2]Ex-4 (B). UV-and radio-detectors were in
series, resulting in a lag time of about 15 sec for the radiotrace. Numbers in the chromatograms refer to the
peak retention time in minutes.
doi:10.1371/journal.pone.0170435.g003
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after activation of the GLP-1 receptor. We attempted to solve these issues by using radioiodi-
nated analogues of the agonist Ex-4 and the antagonist Ex(9–39).
[Nle14,125I-Tyr40-NH2]Ex-4 showed high affinity binding to Ins-1E cells in vitro with a Kd
of 4.1±1.1 nM. The Kd value for [Nle14,125I-Tyr40-NH2]Ex(9–39), however was 4.4 fold higher,
demonstrating a significantly lower affinity towards GLP-1R. In contrast to the radiometal-
labelled GLP-1R tracers, the fraction of internalized [Nle14,125I-Tyr40-NH2]Ex-4 did not
increase with time after reaching the maximum of 3% at 0.5 h. This phenomenon has been pre-
viously described for radioiodinated tracers [9] and is related to the intracellular degradation
and release of the main catabolite 125I-Tyr, which is not trapped in the lysosomal compartment
as do the radiometal-containing catabolites [34]. As a result, some steady state between the
amount of internalized radioactivity and the amount of released radioactivity is reached.
[Nle14,125I-Tyr40-NH2]Ex(9–39) behaved in in vitro binding assays as expected from an antag-
onist. In comparison to the agonist [Nle14,125I-Tyr40-NH2]Ex-4, it showed higher cell membrane
binding but a 5.5-fold-lower internalization into Ins-1E cells. Interestingly, the Bmax value for
the iodinated antagonist was higher (0.070±0.007 versus 0.045±0.003, p<0.05), potentially indi-
cating that it recognizes more binding sites than the iodinated agonist. This feature of the antag-
onist tracer has been described for the SST-2 receptors, where antagonists recognized 10–15 fold
more binding sites, compared to the agonists [24]. However, in spite of the higher number of
binding sites, the lower affinity and lower internalization resulted in a lower total cellular accu-
mulation of the GLP-1R antagonist (2.53%) in comparison to the GLP-1R agonist (4.43%).
In vivo, [Nle14,125I-Tyr40-NH2]Ex-4 demonstrated high and specific tumor uptake, which
was equal to the tumor uptake of 68Ga-Ex-4. But most importantly the kidney uptake was very
low resulting in the high tumor-to-kidney ratio of 9.7. This ratio was even better than the
ratio of 3.5, which we reported for the antagonist 125I-BH-Ex(9–39) [29], and was the highest
among the published GLP-1R tracers. The tumor-to-pancreas ratios were also very similar for
[Nle14,125I-Tyr40-NH2]Ex-4 and
68Ga-Ex-4, which would translate into similar imaging con-
trast for insulinomas against the normal pancreas.
Fig 4. In vitro saturation binding data. The curves show the percent of specifically bound
[Nle14,124I-Tyr40-NH2]Ex-4 after incubation of Ins-1E cells with increasing amounts of peptide. Values
are mean±standard deviation of 3 replicates.
doi:10.1371/journal.pone.0170435.g004
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Somewhat surprisingly, the tumor uptake of the antagonist [Nle14,125I-Tyr40-NH2]Ex(9–39)
was significantly lower, only 12.7±4.05%IA/g at 1 h p.i. and the activity was completely washed
out after 4 h p.i. This may be explained by the higher Kd value of the compound. The kidney
uptake of the iodinated antagonist was identical to the agonist (7.63±1.21%IA/g and 7.51
±0.73%IA/g, respectively), but the tumor-to-kidney ratio and other tumor-to-normal organ
ratios were much lower.
The mechanism behind the low kidney retention of 125I-Ex-4 is related to the non-residua-
lizing nature of the 125I label [34]. After reabsorption and lysosomal degradation in the proxi-
mal tubular cells of the kidneys, the main catabolite 125I-Tyr, is not retained in the lysosomes
but instead freely diffuses out of the cells, and the iodide released upon deiodination rapidly
accumulates in the thyroid tissue and stomach via the sodium iodide symporter. Indeed, the
radioactivity in the thyroid and stomach for both tracers, was effectively blocked by inhibiting
the sodium iodide symporter with irenat.
As we hypothesized, the kidney uptake of the directly iodinated [Nle14,125I-Tyr40-NH2]Ex-4
and [Nle14,125I-Tyr40-NH2]Ex(9–39) (7.5%IA/g) at 1 h p.i. was even lower than that of the Bol-
ton-Hunter-labelled analogue 125I-BH-Ex(9–39) (12.1±1.4%IA/g) [29]. Higher accumulation
of radioactivity in the stomach and the thyroid after injection of [Nle14,125I-Tyr40-NH2]Ex-4
Fig 5. PET images of [Nle14,124I-Tyr40-NH2]Ex-4 and [Nle14,Lys40(Ahx-DOTA-68Ga)NH2]Ex-4
distribution in Ins-1E tumor-bearing mice. Image data are presented as maximum intensity projections
(MIP) at 1 h post injection of [Nle14,124I-Tyr40-NH2]Ex-4 (A) or Nle14,Lys40(Ahx-DOTA-68Ga)NH2]Ex-4 (B).
The middle panel shows an image after blocking the non-specific uptake; the right panel shows an image after
blocking the sodium iodide symporter with irenat.
doi:10.1371/journal.pone.0170435.g005
Fig 6. [Nle14,124I-Tyr40-NH2]Ex-4 tumor time-activity curves. The curves are derived from the PET image
analysis and show the tumor uptake of [Nle14,124I-Tyr40-NH2]Ex-4 versus time.
doi:10.1371/journal.pone.0170435.g006
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and [Nle14,125I-Tyr40-NH2]Ex(9–39) in comparison to
125I-BH-Ex(9–39) [29] confirms more
efficient dehalogenation for the directly iodinated peptides. The relatively fast washout of
activity from the tumor within 4 hours for the directly iodinated agonist can also be explained
by in vivo dehalogenation. Since fast washout of activity from normal organs will result in a
lower radiation exposure, the 124I congener of the directly iodinated Ex-4 agonist may prove a
valuable candidate for clinical PET imaging, provided that an early time-point is chosen for
imaging. However, relatively fast reduction in the tumor uptake of iodinated Ex-4 would limit
the time window for intraoperative localization of insulinoma using a surgical probe, com-
pared to the In-111-labeled Ex-4 analogs used in clinic. Based on the tumor uptake and
tumor-to-normal organ ratios, the optimal imaging time point for the iodinated Ex-4 tracer
would be at 1 hour p.i., which is similar to 68Ga-Ex-4.
As a proof-of-concept, the 124I analogue of the most promising tracer candidate, the agonist
[Nle14,124I-Tyr40-NH2]Ex-4, was evaluated in PET-studies. Although absolute tumor uptake
levels were somewhat lower than expected, the PET-images confirmed the very favourable bio-
distribution profile of the 124I congener in comparison to 68Ga-Ex-4, with a pronounced and
specific tumor uptake and low kidney retention. We strongly believe in the potential of 124I-
and 123I-labeled Ex-4 derivatives for GLP-1 targeted imaging and currently develop automated
labelling strategies. The goal is production of these tracers in high radiochemical purity, spe-
cific activity and improved radiochemical yields, which is an important factor given the high
cost of 123I and 124I in particular, and the activities of these tracers needed for comprehensive
imaging studies in animals and finally for clinical translation.
Conclusions
Even though the antagonist [Nle14,125I-Tyr40NH2]Ex(9–39) recognized more binding sites on
GLP-1R, it had a lower affinity than the agonist and it may not be suitable for clinical transla-
tion. The [Nle14,125I-Tyr40NH2]Ex-4 agonist, in contrast, showed excellent tumor uptake and
at the same time exhibited pharmacokinetics superior to all other GLP-1R tracers presently
available, with particularly high tumor-to-kidney ratio and good contrast to normal organs.
Preclinical PET imaging data strongly suggest that Ex-4 radioiodinated with 124I may be a
promising alternative to the radio-metal labelled derivatives for imaging of GLP-1 receptor
positive insulinoma. It can further improve the sensitivity of the preoperative localization of
benign insulinoma.
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